Mechanisms and risk factors of thromboembolic disease;Mécanismes et facteurs de risque de la maladie veineuse thrombo-embolique

Revue du Praticien

Volumn 46, Issue 10, 1996, Pages 1203-1210

  Emmerich, Joseph ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ORAL CONTRACEPTIVE AGENT;

BLOOD CLOTTING; DRUG SAFETY; FEMALE; HUMAN; RISK FACTOR; SHORT SURVEY; THROMBOEMBOLISM; THROMBOSIS; PATHOPHYSIOLOGY; PREGNANCY; REVIEW; THROMBOPHLEBITIS;

FEMALE; HUMANS; PREGNANCY; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHLEBITIS;

EID: 0029948907     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Browse NL, Burnand KV, Thomas ML. Diseases of the veins. Pathology, diagnosis and treatment. London: Edward Arnold, 1988: 694 pp.
2. Raskob GE, Hulle RD. Venous thrombosis In: Kwaan HC, Samama MM, eds. Clinical thrombosis. CRC Press 1989: 59-89.
3. Kravitz E, Karino T. Pathophysiology of deep vein thrombosis. In: Leclerc JR (eds). Venous thromboembolic disorders. Philadelphia: Lea & Febiger, 1991: 54-64.
4. McLachlin AD, McLachlin JA, Tory TA, Rawling EG. Venous stasis in the lower extremities. Ann Surg 1960; 152: 678-83.
5. Wessler S. Thrombosis in the presence of vascular stasis. Am J Med 1962; 33: 648-66.
6. Warlow C, Ogston D, Douglas AS. Deep venous thrombosis of the legs after strokes. Br Med J 1976; 2: 1178-85.
7. Turpie AGG, Leclerc JR. Prophylaxis of venous thromboembolism. In: Leclerc JR (eds). Venous thromboembolic disorders. Philadelphia: Lea & Febiger, 1991: 303-45.
8. Thomas DP, Merton RE, Wood RD, Hockley DJ. The relationship between vessel wall injury and venous thrombosis: an experimental study. Br J Haematol 1985; 59: 449-53.
9. 2 in venous valve pocket: its possible bearing on thrombogenesis. Br J Surg 1981; 68: 166-71.
10. Stamatakis JD, Kakkar VV, Sagar S, Lawrence D, Nairin D, Bentley PG. Femoral vein thrombosis and total hip replacement Br Med J 1977; 2: 223-5.
11. Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med 1991; 151: 1721-31.
12. Capron L La maladie post-phlébitique. Rev Prat (Paris) 1988; 38: 1897-901.
13. Paltiel O. Epidemiology of venous thromboembolism. In: Leclerc JR (eds). Venous thromboembolic disorders. Philadelphia: Lea & Febiger, 1991: 141-65.
14. Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. In: Colman W, Hirsh J, Marder VJ, Salzman EW (eds). Hemostasis and Thrombosis: Basis Principles and Clinical Practice. 3° édition. Philadelphia: Lippincott, 1994: 1275-96.
15. Collins R, Serimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988; 318: 1162-73.
16. Scurr JH, Coleridge-Smith PD, Hasty JH. Deep venous thrombosis: a continuing problem. Br Med J 1988; 297: 28.
17. Turpie AGG, Levine MN, Hirsh J et al. A double-blind randomized trial of ORG 10172 low-molecular-weight heparinoid in the prevention of deep vein thrombosis in thrombotic stroke. Lancet 1987; 1: 523-6.
18. Verret C, Chauffert B, Lorenzini JL, Lorcerie B. Anomalies de la coagulation au cours des hémopathies malignes et des cancers. Sang Thrombose Vaisseaux 1994; 6: 95-101.
19. Levine MN, Gent M, Hirsh J et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 3 (18): 404-7.
20. Levine M, Hirsh J, Gent M et al. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-9.
21. Gillum RF. Pulmonary embolism and thrombophlebitis in the United States, 1970-1985. Am Heart J 1987; 114: 1262-4.
22. Mossaz A, de Moerloose P, Campana A. Contraception orale et maladies cardiovasculaires. Med Hyg 1993; 51: 124-8.
23. Schulman S, Rhedin AS, Lindmarker P et al. A comparison of six weeks with sixmonths of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.
24. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-thombosis. Lancet 1995; 345: 152-5.
25. Bongard O, Reber G, Bounameaux H, de Moerloose P. Anticardiolipin antibodies in acute venous thromboembolism. Thromb Haemost 1992; 67: 724.
26. Allaart CF, Briët E.: Familial venous thrombophilia. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds). Haemostasis and Thrombosis. Churchill Livingstone, 3° edition, 1994: 1349-60.
27. Aiach M, Gandrille S, Emmerich J, Alhenc-Gelas M, Fiessinger JN. Molecular abnormalities responsible for thrombosis. Genetic aspects. Nouv Rev Fr Hematol 1992; 34: 279-85.
28. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993; 72: 477-80.
29. Gandrille S, Greengard JS, Alhenc-Gelas M et al. Incidence of activated protein resistance caused by the Arg 506 Gln mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood 1995; 86: 219-24.
30. Kœleman BPC, van Rumpt D, Hamulyak K, Reitsma PH, Bertina RM. Factor V Leiden an additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995; 74: 580-3.
31. Dahlback B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923-7.
32. Griffin JH, Evatt B, Wideman C, Fernandez JA Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
33. Koster T, Rosendaal FR, De Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993, 342: 1503-6.
34. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
35. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.